Surrogate markers

A surrogate marker is an indirect measure. In HIV disease, morbidity and mortality are direct markers of disease progression; laboratory tests are surrogate markers of disease progression. Changes in these markers have been shown to affect the long-term risk of death and illness. Surrogate markers in HIV disease include CD4 counts, CD4/CD8 cell ratios, and viral load. Surrogate markers are important in anti-HIV drug trials because the true effects of drugs in slowing HIV disease may not be obvious for many years. Changes in surrogate markers can quickly reveal whether treatment will have any long-term benefits.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.